Uncategorized

Spero bets up to $1.1B for Innovent’s autoimmune antibody

Published

on

Spero Therapeutics is putting over $1 billion on the line in exchange for rights to develop SP001, an anti-CD40L antibody, for IgG4-related disease. A Phase 2 study is planned for the second quarter of 2027.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version